Objective: Rheumatoid arthritis can be classified according to ACPA and RF status. ACPA status may be associated with other pathophysiological differences, e.g., the cytokines driving inflammation. Obesity influences the course of RA, likely involving leptin; the exact mechanisms are not completely understood. This study investigates BMI influence on RA cytokine profiles and the possibility of predicting ACPA status and disease activity measured by Power-Doppler sonography (PDS).

Methods: Patients were examined using a multi-biomarker disease assay and PDS examination of wrists and MCP and PIP joints and stratified according to ACPA status and BMI, using prediction precision to determine BMI cutoff. Analysis was performed using elastic net regularization of logistic and multiple regression. We then attempted to predict ACPA status/PDS activity based on a bootstrap approach.

Results: A total of 120 measurements from 95 patients were performed. ACPA status prediction peaked at BMI 26 kg/m, with AUC 0.82. PDS activity prediction had a mean average error of < 1.6 PDS points for all groups. In obese patients, cytokine profiles appear to align in ACPA-positive and -negative patients, with leptin playing a greater role in predicting PDS activity, but with some remaining differences.

Conclusion: When stratified according to BMI, cytokine patterns can predict ACPA status and PDS activity in RA with a high degree of precision. This indicates that studies into the pathophysiology of RA should take BMI into account, to differentiate between disease- and obesity-associated phenomena. The underlying pathological processes of ACPA-negative and -positive RA appear different. Multi-cytokine evaluations may provide a deeper understanding of disease processes. Key Points • A multi-cytokine approach combined with ultrasonography and modern mathematical methods can contribute to a deeper understanding of the relationship between systemic and joint inflammation. • BMI influences cytokine profiles in rheumatoid arthritis and appears to "override" disease-specific processes. • Using cytokines only, and adjusting for BMI, it is possible to predict the ACPA status and joint inflammation with considerable precision.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-024-07032-0DOI Listing

Publication Analysis

Top Keywords

acpa status
24
disease activity
8
rheumatoid arthritis
8
acpa
7
status
6
body mass
4
mass stratification
4
stratification enables
4
enables cytokine-based
4
prediction
4

Similar Publications

The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis.

Arthritis Res Ther

January 2025

Department of Medical Science and Public Health, Rheumatology Unit, University of Cagliari, Azienda Ospedaliero Universitaria di Cagliari, SS 554 Monserrato (CA), Bivio Sestu, Monserrato, 09042, Italy.

Objectives: To explore the role of newly emerging autoantibodies (AAbs) - peptidyl-arginine deiminase 4 (aPAD4), carbamylated proteins (aCarP), and anti-RA33 (aRA33) - alongside the traditionally assessed rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), in predicting the response to abatacept (ABT) and its retention rate in rheumatoid arthritis (RA) patients.

Methods: Data from 121 consecutive ABT-treated RA patients were recorded. The RF and ACPA status were retrospectively assessed by reviewing the patients' clinical records.

View Article and Find Full Text PDF

Biomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases.

RMD Open

November 2024

Transplantation & Immunogenetics Service, Australian Red Cross Blood Service New South Wales and Australian Capital Territory, Alexandria, New South Wales, Australia.

Objectives: The determinants of rheumatoid arthritis (RA) severity and excess cardiovascular disease (CVD) are incompletely understood. Biomechanical factors are known to influence RA severity. Articular stiffness correlates with arterial and skin stiffness.

View Article and Find Full Text PDF

Clinical presentation and treatment response in ACPA-negative rheumatoid arthritis.

Joint Bone Spine

November 2024

UMR 1227 Lymphocytes B, Auto-immunité et Immunothérapies, University Brest, Inserm, CHU de Brest, Brest, France.

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and potential extra-articular manifestations. This review compares the presentation and treatment response between anti-citrullinated protein antibodies (ACPA)-positive and ACPA-negative RA patients. The incidence of seronegative RA (rheumatoid factor [RF]-negative and ACPA-negative) has increased in recent decades, emphasizing the need for new diagnostic biomarkers.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is associated with high-risk HLA class II alleles known as the "RA shared epitope." Among prevalent shared epitope alleles, study of DRB1*04:04 has been limited. To define relevant epitopes, we identified citrullinated peptide sequences from synovial antigens that were predicted to bind to HLA-DRB1*04:04 and utilized a systematic approach to confirm their binding and assess their recognition by CD4 T cells.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the link between bone erosions and bone mineral density (BMD) in rheumatoid arthritis (RA) patients, suggesting a common pathway.
  • A total of 149 RA patients were analyzed, revealing that higher erosion scores correlated with lower BMD levels, particularly in the hip region.
  • Although autoantibodies like anti-citrullinated peptide antibodies (ACPAs) were associated with increased erosion and lower BMD, the relationship between erosion and BMD isn’t solely driven by these autoimmune factors, indicating the need for osteoporosis screening in these patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!